90 results about "Ectopic expression" patented technology

Transcription factor polynucleotides and polypeptides incorporated into nucleic acid constructs, including expression vectors, have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these constructs have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress). The abiotic stress may include, for example, salt, hyperosmotic stress, water deficit, heat, cold, drought, or low nutrient conditions.

The present invention provides nucleic acid constructs, including plasmids, expression vectors or expression cassettes comprising polynucleotides encoding CCAAT-binding transcription factor polypeptides that have the ability to increase a plant's tolerance to abiotic stress. Polynucleotides encoding functional CCAAT-binding transcription factors were incorporated into expression vectors, introduced into plants, and ectopically expressed. The encoded polypeptides of the invention significantly increased the cold and water deficit tolerance of the transgenic plants, as compared to tolerance to these stresses of control plants.

The present invention provides polynucleotides encoding CCAAT-binding transcription factor polypeptides that modulate the onset of reproductive development in plants. Polynucleotides encoding functional CCAAT-binding transcription factors were incorporated into expression vectors, introduced into plants, and ectopically expressed. The encoded polypeptides of the invention significantly shortened the time to flower development in the transgenic plants, as compared to the flowering time of control plants.

Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.

Polynucleotides and polypeptides incorporated into expression vectors have been introduced into plants and were ectopically expressed. The polypeptides of the invention regulate transcription in these plants and have been shown to confer at least one regulatory activity that results in increased size, biomass, growth rate, and/or yield as compared to a control plan.

Mesenchymal cells are unexpectedly found to express specific truncated versions of immunoglobulin (Ig) superfamily members, Igμ heavy chain and Igδ heavy chain variants. Mesenchymal Ig heavy chain gene products either directly or indirectly control hemopoietic stem cells. Ectopic expression, RNAi or antibody therapy can be used to modulate Ig heavy chain mediated functions.

The invention provides an intensive antitumor medicament, namely bestatin deanol ester, a preparation method and application thereof. The bestatin deanol ester not only can effectively inhibit ectopic expression of aminopeptidase N activity, but also greatly improve the water solubility of the parent drug bestatin of the bestatin deanol ester, has slow release effect, is more excellent than the parent drug bestatin either from healing effect or preparation, and has wide application. Particularly, the invention mainly relates to the following three aspects: (1) design and synthesis of the bestatin deanol ester; (2) N'N deanol which is a micromolecule fragment, can be connected with other medicaments containing carboxyl, improves the pharmacokinetic property of the medicaments, and improves water solubility; and (3) a method for synthesizing an ester substance to which the invention relates with wide application and mild condition.

The invention relates to methods and substances for the targeted alteration of genetic information on an RNA level. The substances are artificially produced guide RNAs, which are capable of recruiting endogenous editing enzymes, such as hADAR enzymes, in particular hADAR2 and hADAR1, in order to introduce targeted point mutations in selected mRNAs. The guide RNA consists of multiple segments and is constructed in such a way that individual nucleotides from different segments pair to form a double helix, and the nucleotides of a determined segment form a hairpin structure within the guide RNA. The invention also relates to the method for directed RNA editing, wherein the guide RNA is transfected into the cells in which the RNA editing is to be carried out. The substances and the method can be used for repairing individual, e.g. disease-relevant point mutations, such as those leading to premature stop signals. An advantage of the invention is that endogenous editing enzymes are also used in order to introduce targeted point mutations into the RNA. Only the short guide RNA, used for recruiting endogenous editing enzymes, must be artificially produced for each specific problem and ectopically expressed.

An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8 fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interfered with EGF activation of the EGF receptor in cotransfected cells demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression. For both p185HER-2 and the EGF receptor, the extent of inhibition was affected by the expression levels of herstatin relative to the receptor. Herstatin is an autoinhibitor of p185HER-2 and expands its inhibitory activity to another member of the group I family of receptor tyrosine kinases, the EGF receptor.

The present invention provides in one aspect novel fusion partner cells that ectopically express one or more genes that alter the phenotype of a hybrid cell made from a fusion of the fusion partner cell and a fusion cell, hybrid cell lines produced using the fusion partner cells. The invention in another aspect provides antibodies produced by certain hybrid cell lines, and compositions containing one or a combination of such antibodies or antigen-binding fragments thereof. The invention also provides in another aspect methods of using the antibodies or antigen-binding fragments thereof for diagnosis and treatment of diseases characterized by the antigens specifically bound by the antibodies.

The invention discloses application of inhibiting accumulation of xantheins while accumulating lycopene and anthocyanin in preparation of Brassica plants with red pedals. The application is specifically as follows: interfering with the gene expression of LCYB, LCYE, MYB12 and MYB111 and simultaneously performing ectopic expression of TT8 genes. The invention further discloses a preparation expression vector for interfering with the gene expression of LCYB, LCYE, MYB12 and MYB111 and simultaneously performing ectopic expression of the TT8 genes and a preparation method of the vector. By interfering with the gene expression of LCYB, LCYE, MYB12 and MYB111, the xantheins, namely carotenoid and flavonol are inhibited; and by performing the ectopic expression of the TT8 genes, the accumulation of lycopene and anthocyanin can be promoted, so that the pedals are red, the Brassica plants with the red pedals are successfully prepared, and the flower colors of the Brassica plants are enriched.

The invention belongs to the field of biological pharmacy and provides a monoclonal antibody for resisting cell surface ectopic expression. The amino acid sequence of a light chain variable region at the Fab fragment antigen-binding site of an antibody molecule is shown as SEQ ID NO:2, and the amino acid sequence of a heavy chain variable region is shown as SEQ ID NO:4. The invention also provides application of the monoclonal antibody in preparation of medicaments for treating and preventing digestive tract tumors or digestive tract tumor metastasis. The invention also provides a detection kit and medicinal composition containing the monoclonal antibody. The invention also provides a preparation method of the monoclonal antibody. A series of in vivo and in vitro tests prove that the purified and degermed monoclonal antibody has high affinity for PALP and/or IALP antigen for resisting extracellular ectopic expression of tumor cells and has a biological activating function of inhibiting growth and migration of tumor cells.

The present invention provides a non-naturally occurring seed plant that is characterized by delayed seed dispersal due to ectopic expression of a nucleic acid molecule encoding an AGL8-like gene product. Further provided herein is a non-naturally occurring seed plant, such as an agl1 agl5 double mutant, that is characterized by delayed seed dispersal due to suppression of AGL1 and AGL5 expression in the seed plant. The invention also provides a substantially purified dehiscence zone-selective regulatory element, which includes a nucleotide sequence that confers selective expression upon an operatively linked nucleic acid molecule in the valve margin or dehiscence zone of a seed plant. Also provided by the invention are kits for producing a transgenic seed plant characterized by delayed seed dispersal, such kits containing a dehiscence zone-selective regulatory element.

The invention discloses application of a gene for interfering expression of LCYB and LCYE and simultaneously ectopically expressing TT8 in preparation of a brassica plant having red petals. The invention further discloses an expression vector for preparing the gene for interfering expression of LCYB and LCYE genes and simultaneously ectopically expressing TT8 gene and a preparation method of the vector. Yellow carotenoid is inhibited and red lycopene is accumulated by interfering expression of the LCYB and LCYE genes; accumulation of cyanin can be promoted through ectopic expression of the TT8 gene; therefore, the petals are red; the brassica plant having red petals is successfully prepared; and colours of the brassica plants are enriched.

The invention provides a novel HIV recombined multi-epitope fusion antigen and a detection kit for preparing through the antigen. Flexible structured genes are added into the main epitope genes of HIV-1 gp41, M group and O group, the main epitope genes of HIV-1gp120 and the main epitope genes of HIV-2gp36, so that all the gene DNA are linked to be an artificial gene sequence. The sequence is cloned to an expression vector for ectopic expression, so as to establish immunocompetent high-expression cell strain, finally the sequence is fermented and induced into efficient expression, and chromatographic separation and purification is performed on the multi-antigen epitope fusion antigen of the HIV. The antigen is applied to the immune detection reagent, as the unnecessary gene sequence is reduced through the fusion antigen, the non-specific action is reduced for more than 50%, and the synergistic effect of the multi-antigen epitope of the same antigen increases the detection sensitivity to be 2 to 3 times.

Disclosed is a new system for generating recombinant adenovirus vectors and adenovirus-based expression libraries, by positive selection of recombinants deleted for the endogenous protease gene, which gene is expressibly cloned into another region of the adenoviral genome. In a preferred embodiment, the invention allows positive selection of E1-deleted, protease-deleted recombinant adenovirus vectors comprising an exogenous gene or an expressible piece of exogenous DNA, by providing an expression cassette comprising the protease gene and the exogenous DNA inserted in place of E1 region in a shuttle vector. In vivo recombination of the shuttle vector with a protease-deleted adenoviral genome in suitable non-complementing cells generates viable recombinants only when rescuing the protease cloned in E1 region. Non-recombinant viral genomes are not able to grow due to the deletion of the protease gene, ensuring that only recombinant viral plaques are generated. This positive selection can be used for the generation of a large number of high purity recombinant adenovirus vectors and allows generation of adenovirus-based libraries with diversity exceeding 10⁶ clones.